Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer

Journal: Nature Medicine

Published: 2018-07-23

DOI: 10.1038/s41591-018-0091-x

Affiliations: 15

Authors: 20

Go to article
Institutions FC
The Imperial Centre for Translational and Experimental Medicine (ICTEM), AHSC, United Kingdom (UK) 0.35
Centre for Pathology, ICL, United Kingdom (UK) 0.10
MTA TTK Lendület Cancer Biomarker Research Group, Hungary 0.08
Department of Biochemistry and Molecular Biology, University of Debrecen, Hungary 0.05
Case Comprehensive Cancer Center (Case CCC), CWRU, United States of America (USA) 0.05
Department of Genetics and Genome Sciences, CWRU, United States of America (USA) 0.05
Charing Cross Hospital, Imperial College Healthcare NHS Trust, United Kingdom (UK) 0.05
IRCCS Division of Pathology, Italy 0.05
AstraZeneca IMED Biotech Unit Cambridge, United Kingdom (UK) 0.05
Breast Unit, The Royal Marsden NHS Foundation Trust, United Kingdom (UK) 0.05
IRCCS Department of Pathology and Laboratory Medicine, Italy 0.05
2nd Department of Paediatrics, SE, Hungary 0.03
Institute of Translational Medicine (ITM), University of Liverpool, United Kingdom (UK) 0.02
The Clatterbridge Cancer Centre NHS Foundation Trust, United Kingdom (UK) 0.02
Royal Liverpool University Hospital, The Royal Liverpool and Broadgreen University Hospitals NHS Trust, United Kingdom (UK) 0.02